ImmuPharma plc (LON:IMM – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 3.02 and last traded at GBX 3.21, with a volume of 3799658 shares trading hands. The stock had previously closed at GBX 3.50.
ImmuPharma Stock Down 1.3%
The company has a market capitalization of £21.52 million, a PE ratio of -9.32 and a beta of 3.01. The business has a 50 day simple moving average of GBX 3.87 and a 200 day simple moving average of GBX 4.47.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a negative return on equity of 633.14% and a net margin of 3,519.56%. Equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- IonQ and NVIDIA Just Cracked a Major Quantum Computing Bottleneck
- This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
